Morgan Stanley raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $183 from $180 and keeps an Overweight rating on the shares after the company announced a settlement of ongoing patent litigation with Avadel (AVDL) over high sodium oxybate Lumryz. The firm now includes royalty revenues from Lumryz in its estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals: Buy Rating Affirmed Amid Legal Settlement and Strategic Stability
- Jazz Pharmaceuticals Settles Disputes with Avadel
- Wells Fargo says Avadel settlemnet adds $5 to Jazz Pharmaceuticals DCF
- Avadel announces global settlement of all litigation with Jazz Pharmaceuticals
- Jazz Pharmaceuticals price target raised to $180 from $167 at Morgan Stanley